Fluoxetine v. placebo in prevention of relapse
in post-traumatic stress disorder
by
Martenyi F, Brown EB, Zhang H, Koke SC, Prakash A.
Novartis Pharmaceuticals,
Basel, Switzerland.
Br J Psychiatry 2002 Oct;181:315-20

ABSTRACT

BACKGROUND: Little is known about the effect of pharmacotherapy in the prevention of post-traumatic stress disorder (PTSD) relapse. AIMS: To assess the efficacy and tolerability of fluoxetine in preventing PTSD relapse. METHOD: This was a double-blind, randomised, placebo-controlled study. Following 12 weeks of acute treatment, patients who responded were rerandomised and continued in a 24-week relapse prevention phase with fluoxetine (n=69) or placebo (n=62). The primary efficacy assessment was the prevention of PTSD relapse, based on the time to relapse. RESULTS: Patients in the fluoxetine/fluoxetine group were less likely to relapse than patients in the fluoxetine/placebo group (P=0.027). There were no clinically significant differences in treatment-emergent adverse events between treatment groups. CONCLUSIONS: Fluoxetine is effective and well tolerated in the prevention of PTSD relapse for up to 6 months.

PTSD
Fluoxetine.info
Antidepressants
Partial responders
Fluoxetine weekly
Fluoxetine and LSD
Fluoxetine and PMT
Fluoxetine and MAO-A
Fluoxetine and MAO-B
Fluoxetine and weight
Fluoxetine and bipolars
Fluoxetine and oxytocin
Fluoxetine : side-effects
Fluoxetine every third day
Fluoxetine (Prozac) : structure
PTSD: SSRIs versus Non-SSRIs
Fluoxetine and the opioid pathways

Refs
HOME
HedWeb
Future Opioids
BLTC Research
Paradise-Engineering
Utopian Pharmacology
The Hedonistic Imperative
When Is It Best To Take Crack Cocaine?

The Good Drug Guide
The Responsible Parent's Guide
To Healthy Mood Boosters For All The Family